Fish oil supplementation decreases serum soluble receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in female patients with rheumatoid arthritis

Clinical Biochemistry

Volumn 43, Issue 6, 2010, Pages 576-580

  Kolahi, Sousan ^a   Ghorbanihaghjo, Amir ^a   Alizadeh, Samira ^a   Rashtchizadeh, Nadereh ^b   Argani, Hassan ^a   Khabazzi, Ali Reza ^a   Hajialilo, Mehrzad ^a   Bahreini, Elham ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Fish oil; Osteoprotegerin; Rheumatoid arthritis; Soluble receptor activator of nuclear factor kappa B ligand; Tumor necrosis factor alpha

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN; FISH OIL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD SAMPLING; BONE METABOLISM; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; BONE AND BONES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; FISH OILS; HUMANS; MIDDLE AGED; OSTEOPROTEGERIN; PLACEBOS; RANK LIGAND; SOLUBILITY; YOUNG ADULT;

EID: 77950865389     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.12.011     Document Type: Article

References (49)

1. Romas E., Gillespie M.T., Martin T.J. Involvement of receptor activator of NF kappa B ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
2. Zhao B., Takami M., Miyamoto Y., et al. Characterization of synovial cell clones isolated from rheumatoid arthritis patients: possible involvement of TNF-alpha in reduction of osteoprotegerin in synovium. Cytokine 2008, 41:61-70.
3. Bhattacharya A., Rahman M., Banu J., et al. Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids. J. Am. Coll. Nutr. 2005, 24:200-209.
4. Laan R.F., van Riel P.L., van de Putte L.B., van Erning L.J., van't Hof M.A., Lemmens J.A. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann. Intern. Med. 1993, 119:963-968.
5. Adachi J.D., Bensen W.G., Hodsman A.B. Corticosteroid-induced osteoporosis. Semin. Arthritis. Rheum. 1993, 22:375-384.
6. Cooper C., Coupland C., Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann. Rheum. Dis. 1995, 54:49-52.
7. Wittersheim E., Mesquita M., Demulder A., et al. OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis. Clin. Biochem. 2006, 39:617-622.
8. McClung M. Role of RANKL inhibition in osteoporosis. Arthritis Res. Ther. 2007, 9(Suppl 1):S3.
9. Saidenberg-Kermanac'h N., Cohen-Solal M., Bessis N., De Vernejoul M.C., Boissier M.C. Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 2004, 71:9-13.
10. Poulsen R.C., Wolber F.M., Moughan P.J., Kruger M.C. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. Prostaglandins Other Lipid. Mediat. 2008, 85:42-48.
11. Vega D., Maalouf N.M., Sakhaee K. CLINICAL review #: the role of receptor activator of nuclear factor-kappa B (RANK)/RANK ligand/osteoprotegerin: clinical implications. J. Clin. Endocrinol. Metab. 2007, 92:4514-4521.
12. Horner K.C. The effect of sex hormones on bone metabolism of the otic capsule-an overview. Hear. Res. 2009, 252:56-60.
13. Geusens P.P., Landewe R.B., Garnero P., et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 2006, 54:1772-1777.
14. Hofbauer L.C., Heufelder A.E. The role of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum. 2001, 44:253-259.
15. Keystone E.C. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 2001, 27:427-443.
16. Bezerra M.C., Carvalho J.F., Prokopowitsch A.S., Pereira R.M. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz. J. Med. Biol. Res. 2005, 38:161-170.
17. Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999, 25:255-259.
18. Kremer J.M. n-3 fatty acid supplements in rheumatoid arthritis. Am. J. Clin. Nutr. 2000, 71:349S-351S.
19. Kremer J.M., Lawrence D.A., Jubiz W., et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum. 1990, 33:810-820.
20. James M.J., Proudman S.M., Cleland L.G. Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis. Prostaglandins Leukot. Essent. Fatty Acids 2003, 68:399-405.
21. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21:495-505.
22. Sun D., Krishnan A., Zaman K., Lawrence R., Bhattacharya A., Fernandes G. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J. Bone Miner. Res. 2003, 18:1206-1216.
23. Watkins B.A., Li Y., Lippman H.E., Feng S. Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism. Prostaglandins Leukot. Essent. Fatty Acids 2003, 68:387-398.
24. Weiss L.A., Barrett-Connor E., von Muhlen D. Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo Study. Am. J. Clin. Nutr. 2005, 81:934-938.
25. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31:315-324.
26. van Gestel A.M., Anderson J.J., van Riel P.L., et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J. Rheumatol. 1999, 26:705-711.
27. Kwan T.S., Padrines M., Theoleyre S., Heymann D., Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004, 15:49-60.
28. Bolon B., Shalhoub V., Kostenuik P.J., et al. Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum. 2002, 46:3121-3135.
29. Stolina M., Adamu S., Ominsky M., et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J. Bone Miner. Res. 2005, 20:1756-1765.
30. Romas E., Bakharevski O., Hards D.K., et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 2000, 43:821-826.
31. Oelzner P., Franke S., Lehmann G., et al. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis-relationship with bone mineral density, disease activity and bone turnover. Clin. Rheumatol. 2007, 26:2127-2135.
32. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12:1260-1268.
33. Mizuno A., Amizuka N., Irie K., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 1998, 247:610-615.
34. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 2008, 29:155-192.
35. Neumann T., Oelzner P., Petrow P.K., et al. Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis. Inflamm. Res. 2006, 55:32-39.
36. Ominsky M.S., Li X., Asuncion F.J., et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J. Bone Miner. Res. 2008, 23:672-682.
37. Schett G., Redlich K., Hayer S., et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum. 2003, 48:2042-2051.
38. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
39. Gravallese E.M., Manning C., Tsay A., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000, 43:250-258.
40. Takayanagi H., Iizuka H., Juji T., et al. Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000, 43:259-269.
41. Itonaga I., Fujikawa Y., Sabokbar A., Murray D.W., Athanasou N.A. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J. Pathol. 2000, 192:97-104.
42. Hein G.E., Meister M., Oelzner P., Franke S. sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis. Rheumatol. Int. 2008, 28:765-769.
43. Coetzee M., Haag M., Kruger M.C. Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells. J. Nutr. Biochem. 2007, 18:54-63.
44. Das U.N. Essential fatty acids and osteoporosis. Nutrition 2000, 16:386-390.
45. Kettler D.B. Can manipulation of the ratios of essential fatty acids slow the rapid rate of postmenopausal bone loss?. Altern. Med. Rev. 2001, 6:61-77.
46. Gonzalez-Alvaro I., Ortiz A.M., Tomero E.G., et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann. Rheum. Dis. 2007, 66:1675-1678.
47. Zhao B., Takami M., Miyamoto Y., et al. Characterization of synovial cell clones isolated from rheumatoid arthritis patients: possible involvement of TNF-alpha in reduction of osteoprotegerin in synovium. Cytokine 2008, 41:61-70.
48. Venkatraman J.T., Chu W.C. Effects of dietary omega-3 and omega-6 lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. J. Am. Coll. Nutr. 1999, 18:602-613.
49. Leeb B.F., Sautner J., Andel I., Rintelen B. Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study. Lipids 2006, 41:29-34.